Combined Therapy of Rhein and Benazepril on the Treatment of Diabetic Nephropathy in db/db Mice

Abstract

Objective: Rhein and angiotensin-converting enzyme inhibitor (ACEI) have been reported to prevent the progression of diabeic nephropahthy (DN). We futher explore the unknown ability to induce renal-protection of rhein and ACEI combined therapy in DN compared with the therapeutic effects of single treatment of them by using db/db mouse of type 2 diabetes model.

Methods: db/db and db/m mice, 8 weeks of age, were divided into five groups according to the following treatments: (A) db/m, given saline treatment; (B) db/db, given saline treatment; C db/db, given rhein treatment (150 mg/kg/day); (D) db/db, given benazepril treatment (10 mg/kg/day); (E) db/db, given rhein (150 mg/kg/day) with benazepril (10 mg/kg/day). Body weight, plasma glucose, plasma lipid and 24 h urinary albumin excretion levels were measured every 4 weeks. Morphometry of renal tissue and immunohistology of transforming growth factor-β1 (TGF-β) and fibronectin were determined for all groups at the end of the treatment.

Results: It was found that after treatment urinary albumin excretion was reduced after 4 weeks treatment in group E and after 8 weeks treatment in groups C and D, when compared to group B (p<0.05). Plasma creatinine levels dropped significantly for group E, compared with the diabetic control group by the end of the treatment period. Futhermore, after the treatment body weight, plasma glucose, cholesterol, triglyceride and low density lipoprotein all decreased in groups C and E compared to group B (p<0.05). Histological morphometric analysis revealed that the whole glomerular area and extracellular matrix area was significantly reduced in groups C, D and E compared to group B, at 20 weeks of age, an effect most pronounced in group E. Using immunohistochemistry, the expression of fibronectin and TGF-β1 in groups C, D and E was found to have decreased compared to group B, after 12 weeks treatment, again the effect being more pronounced in group E.

Conclusions: There appeared to be a similar renal protective effect of rhein compared with benazepril in diabetic nephropathy. A combined therapy may offer a more beneficial complementary effect on kidney injury in db/db mice, as reflected by urinary albumin excretion, renal function and histological changes. Our findings suggest that a therapeutic approach that combines rhein with ACEI provides a more effective therapy for DN than does either agent alone.

Key words

rhein - benazepril - db/db mouse - diabetic nephropathy

References

• 1 Leon CA, Raij L. Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy.  J Hypertens. 2005;  23 1931-7
• 2 Benigni A, Zoja C, Corna D. et al . Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat.  J Am Soc Nephrol. 2003;  14 1816-24
• 3 Zoja C, Corna D, Camozzi D. et al . How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach.  J Am Soc Nephrol. 2002;  13 2898-908
• 4 Raimondi L, Banchelli Soldaini G, Buffoni F. et al . Rhein and derivatives. In vitro studies on their capacity to inhibit certain proteases.  Pharmacol Res Commun. 1982;  14 103-112
• 5 Kean EA, Gutman M, Singer TP. Rhein, a selective inhibitor of the DPNH-flavin step in mitochondrial electron transport.  Biochem Biophys Res Commun.. 1970;  40 1507-1513
• 6 Kiritoshi S, Nishikawa T, Sonoda K. et al . Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy.  Diabetes. 2003;  52 2570-7
• 7 Dai CS, Liu ZH, Chen HP. Effects of rhein on inhibiting the progression of diabetic nephropathy in STZ-induced diabetic rats.  J Nephrol Dial Transplant. 1998;  8 413-505
• 8 Zhu JM, Liu ZH, Huang YF. Therapeutic effect of rhein on diabetic nephropathy in db/db mice.  J Nephrol Dial Transplant. 2002;  11 3-10
• 9 Guo XH, Liu ZH, Peng A. Rhein restards the progression of type 2 diabetic nephropathy.  Chin J Nephrol. 2002;  18 280-284
• 10 Liu ZH, Li YJ, Chen ZH, Liu D, Li LS. Glucose transporter in human glomerular mesangial cells modulated by transforming growth factor-beta and rhein.  Acta Pharmacol Sin. 2001;  22 169-75
• 11 Zhu J, Liu Z, Huang H, Chen Z, Li L. Rhein inhibits transforming growth factor beta1 induced plasminogen activator inhibitor-1 in endothelial cells.  Chin Med J (Eng). 2003;  116 354-9
• 12 Zhang J, Liu Z, Chen Z, Li Y, Li L. Effect of rhein on glucose transporter-1 expression and its function in glomerular mesangial cells.  Chin Med J (Engl). 1999;  112 1077-1079
• 13 O’Connor AS, Schelling JR. Diabetes and the kidney.  Am J Kindney Dis. 2005;  46 766-73
• 14 Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy.  J Am Soc Nephrol. 2005;  16 ((Suppl 1)) S30-3
• 15 Tamura J, Konno A, Hashimoto Y, Kon Y. Upregulation of renal renin-angiotensin system in mouse diabetic nephropathy.  Jpn J Res. 2005;  53 13-26
• 16 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 17 Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD. Glomerular permselectivity in early stages of overt diabetic nephropathy.  Kidney Int. 2000;  58 2129-2137
• 18 Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis.  Kidney Int. 2001;  59 260-269
• 19 Cooper ME, Jandeleit-Dahm KA. Lipids and diabetic renal disease.  Curr Diab Rep. 2005;  5 445-8
• 20 S’Vaquero M, Pastor C, Galimany R, Romero R. Fosinopril ameliorates exogenous cholesterol-induced incipient glomerular lesions in obese Zucker rats. Effects on eicosanoid secretion.  Nephrol Dial Transplant. 1998;  13 2227-33
• 21 Fuad N, Ziyadeh Brenda B, Hoffman Dong, Cheol Han M. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice.  PNAS. 2000;  14 8015-8020
• 22 Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.  FASEB J. 2000;  14 439-447
• 23 Guo XH, Liu ZH, Dai CS, Li H, Liu D, Li LS. Rhein inhibits cell hypertrophy and accumulation of extracellular matrix in renal tubular epithelial cells inducedby transforming growth factor β1.  Acta Pharmacol Sin. 2001;  22 934-938
• 24 Brownlee M. A radical explanation for glucose-induced beta cell dysfunction.  J Clin Invest. 2003;  112 1788-90
• 25 Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.  Diabetes Metab. 2004;  30 487-96
• 26 Luno J, Praga M, de Vinuesa SG. The reno-protective effect of the dual blockade of the rennin angiotensin system.  Curr Pharm Des.. 2005;  11 1291-1300
• 27 Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.  BMJ. 2000;  321 1440-1444

Correspondence